Download BIOGRAPHICAL SKETCH NAME: Suresh C. Tyagi eRA COMMONS

OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015)
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.
NAME: Suresh C. Tyagi
eRA COMMONS USER NAME (credential, e.g., agency login): S0TYAG01@LOUISVILLE.
POSITION TITLE: Endowed Chair Professor
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)
INSTITUTION AND LOCATION
University of Aligarh, India
University of Aligarh, India
University College, Cork, Ireland
SUNY at Stony Brook, NY, USA
SUNY at Stony Brook, NY, USA
DEGREE
(if
applicable)
M.Phil.
Ph.D.
Post-Grad
Post-Doc
Res Assoc
Completion
Date
MM/YYYY
1977
1980
1983
1987
1989
FIELD OF STUDY
Chemistry
Biophysics
Bioinorganic Chemistry
Pharmacology
Pathology
A. Personal Statement:
Our lab is one of the leaders in the field of role of MMP/TIMP axis in the muscle biology and extracellular matrix
remodeling that play essential role in the replacement or repair of damaged, missing or poorly functioning heart
and musculoskeletal tissues, including the skeletal muscle and the cardiac muscle remodeling. Also we have
published numerous articles on the role of exercise in mitigation of diabetic complications. Also the role of H2S as
protective agents has been studies in our laboratory. Therefore, we are in the situation to execute the experiments
proposed in this proposal.
B. Positions and Honors:
1989-1991 Instructor, Biochemistry & Cell Biology, SUNY-Stony Brook, New York
1992-1996 Assistant Professor, Medicine & Biochemistry, University of Missouri-Columbia, Missouri
1996-2003 Associate Professor, Physiology & Biophysics, Univ of Mississippi Medical Center, Jackson, MS
2003-present Professor, Physiology & Biophysics, University of Louisville, Louisville, Kentucky
2003-present Stodghill Endowed Chair in Biomedical Sciences, University of Louisville, Louisville, Kentucky
2003-present Vice Chair for Research, Physiology & Biophysics, University of Louisville, Louisville, Kentucky
Awards and Professional Activities:
1978-1980 Research Fellowship, University Grants Commission, India
1980-1982 Senior Demonstratorship, University of Cork, Ireland
1991 American Society of Biochemistry & Molecular Biology, Travel Award for the 15th International Congress of
Biochemistry, Jerusalem, Israel
1992 International Union of Biochemistry & Molecular Biology, Travel Award for the Ist conference on the
Biochemistry of Diseases, Nayoga, Japan
1995 American Heart Association, Boots Cardiovascular Research Prize, Finalist, Feb 1-4, 1995, Snowbird
Conference Center, Salt Lake City, Utah
1995 Travel Award, 7th Intern Symp Basement Membrane, NIH-NIDDKD, 06/29-30, 1995.
1998 Astra Merck Faculty Travel Award, Pathophysiology of Myocardial Stunning, Hibernation and Preconditioning,
Oct 15-17, 1998, Taormina-SiCily-Italy
 PHS 398/2590 (Rev. 05/01)
Page _______
Biographical Sketch Format Page 
2000 AstraZeneca Faculty Travel Award, Euro Society Cardiology, August 26-30, 2000, Amsterdam,
2001 AstraZeneca Apollo Faculty Award.
2001 Medal of Merit, ISHR, XVII World Congress Winnipeg, Canada.
Editorial Board, Fellowship and Committee:
2004-2007 Journal of Molecular and Cellular Cardiology;1999- Am J Physiol (Heart & Circulatory Physiology); 2001Clinical & Experimental Hypertension; 2003- Molecular Cellular Biochemistry;
Fellowship: 2000-AHA; 2002-APS (Cardiovascular Section); Member of APS-Fellowship Committee (2003-2006);
Awards Committee (2006-2009).
Study Section Member: 1997-2005 AHA Southeast-Ohio Valley (Vascular Biology); 2000-2003 AHA National (Molecular
Signal I); NIH 2003 RFA; NIH-ECS; 2004 PPG; VCMB; NCI-IMAT; 2005-NIAMS; ESTA; RFA-NIDDK; 2006-2010-MIM;
NIH/BINP/MTE/SBIR/HM/SEP/grant reviewer (Ad Hoc) 2000 - present
C. Contributions to Science:
1. Our lab is the FIRST to discover the activation of latent matrix metalloproteinases (MMPs) in the heart.
a) Tyagi SC. Matsubara L, Ratajska A, Weber KT. Identification and localization of myocardial
collagenases(s), Clin Res, 40:757A, 1992.
b) Tyagi SC, Matsubara L & Weber KT. Direct extraction and estimation of callagenase(s) activity by
zymography in microquantities of rat myocardium and uterus, Clin Biochem, 26:191-198, 1993.
c) Tyagi SC & Cleutjens JPM. Myocardial collagenase: purification and structural characterization, Canad
J Cardiol, 12:165-171, 1995.
d) Tyagi SC, Kumar SG, Banks J & Fortson W. Co-expression of Tissue Inhibitor and Matrix
Metalloproteinase in Myocardium, J Mol Cell Cardiol, 27:2177-2189, 1995.
2. The term myocardial remodeling was coined in our laboratory by identifying the MMPs in the heart and MMP
functional proteome was discovered in my laboratory by running the first 2-D zymographic gel in the world.
a) Tyagi SC, Haas SJ, Kumar SG, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA &
Curtis JJ. Post-trancriptional regulation of extracellulr matrix metalloproteinse in human heart endstage failure secondary to ischemic cardiomyopathy, J Mol Cell Cardiol, 28:1415-1428, 1996.
b) Tyagi SC, Kumar SG, Alla SR, Reddy HK, Voelker DJ & Janicki JS. ECM Regulation of
Metalloproteinase & Antiproteinase in Human Heart Fibroblasts, J Cell Physiol, 167:137-147, 1996.
c) Tyagi SC, Kumar SG, Voelker DJ, Reddy HK, Janicki JS & Curtis JJ. Differntial gene expression of
extracellular matrix components in dilated cardiomyopathy, J Cell Biochem, 63:185-198, 1996.
d) Tyagi SC, Lewis K, Pikes D, Marcello A, Mujumdar V, Smiley L, Moore CK. Stretch induced
membrane type matrix metalloproteinases and tissue plasminogen activator in cardiac fibroblast cells,
J Cell Physiol, 176:374-382, 1998.
e) Miller A, Mujumdar V, Shek E, Guillot J, Angelo M, Pakmer L, Tyagi SC. Hyperhomocysteinemia
induces multiorgan damage, Heart & Vessels, 15(3):135-143, 2000.
3.
We were the first to discover decrease in elastin/collagen ratio in atherosclerosis.
a) Tyagi SC, Meyer L, Schmaltz RA, Reddy HK & Voelker DJ. Proteinases and Restenosis in Human
Coronary Artery: Extracellular Matrix Production Exceeds the Expression of Proteolytic Activity,
Atherosclerosis, 116:43-57, 1995.
b) Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in
vascular cells, Am J Physiol, 274:C396-C405, 1998.
c) Tummalapalli CM, Tyagi SC. Response of vascular smooth muscle cells to extracellular matrix
degradation, J Cell Biochem, 75:515-527, 1999.
d) Cox MJ, Hawkins UA, Hoit BD, Tyagi SC. Attenuation of oxidative stres and remodeling by cardiac
inhibitor of metalloproteinase protein transfer, Circulation, 109(17):2123-2128, 2004.
4.
We are the first to identify the tissue levels of homocysteine in atherosclerotic plaques.
a) Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, Parker JL. Reduction-oxidation (redox) and vascular
tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in vascular
extracellular matrix remodeling and vascular tone, Mol Cell Biochem, 181:107-116, 1998.
b) Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in
vascular cells, Am J Physiol, 274:C396-C405, 1998.
c) Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial
function, J Cell Biochem, 82(3):491-500, 2001
d) Sood HS, Cox MJ, Tyagi SC. Generation of Nitrotyrosine Precedes the Activation of Matrix
Metalloproteinase in Left Ventricle of Hyperhomocystenemia Rats, Antioxidant & Redox Signaling,
4(5):799-804, 2002.
 PHS 398/2590 (Rev. 05/01)
Page _______
Biographical Sketch Format Page 
Complete List of Published Work in PubMed: http://www.ncbi.nlm.nih.gov/pubmed/?term=Tyagi+SC%2C
D. Research Support:
2R01 HL-74185, 250,000/year direct cost, Tyagi-PI 9/1/2003-2/1/2019 “Reversing diabetic muscle myopathy by
exercise and exosomes”. The major goals of this project are to study cardiac endothelial myocyte function in chronic
left ventricular volume overload heart failure.
R01 HL108621, 250,000/year direct cost, Tyagi-PI 4/1/2011-12/31/2016 “Mitogenic and anti-angiogenic mechanisms
of heart failure”. The major goals of this project are to study angiogenesis and mitochondrial mitophagy in chronic left
ventricular pressure overload heart failure.
RO1 NS-84823, 170,000/year, Tyagi-MPI 7/1/1913-6/30/2018 "Mechanisms of Homocysteine-induced FibrinogenAmyloid Plaque Formation”. The major goal of this project is determine role of homocysteine in vascular dementia and
Alzheimer.
RO1 DK 104653-01, 180,000/year Tyagi-MPI, 07/01/2015-06/30/2020 “Hydrogen sulfide mechanism of renal
hypertension”. The major goal of this project is to determine mechanism of renal remodeling and role of H2S.
RO1 AR067667-01, 190,000/year Tyagi-MPI, 09/01/2015-08/31/2020 “Mitigating mitochondrial epigenetics in bone
remodeling by hydrogen sulfide”. The major goal of this project is to determine the mechanism of bone remodeling
and epigenetics.
 PHS 398/2590 (Rev. 05/01)
Page _______
Biographical Sketch Format Page 